Mixed effects modeling of weight change associated with placebo and pregabalin administration

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 34, Issue 6, 2007, Pages 753-770

  Frame, Bill ^a   Beal, Stuart L ^b   Miller, Raymond ^a   Barrett, Jeannette ^a   Burger, Paula ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mixed effects; NONMEM; Pregabalin; Unbounded likelihood; Weight change

Indexed keywords

PLACEBO; PREGABALIN;

ARTICLE; DRUG HALF LIFE; HUMAN; MODEL; OPEN STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WEIGHT CHANGE;

BODY WEIGHT; CLINICAL TRIALS AS TOPIC; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MODELS, BIOLOGICAL; PLACEBOS;

EID: 36448986011     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-007-9067-z     Document Type: Article

References (36)

1. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R and Woodruff GN (1996). The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha-2-delta subunit of a calcium channel. J Biol Chem 271: 5768-5776
2. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42: 229-236
3. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 280: 107-110
4. 3H] nore- pinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 295: 1086-1093
5. 3H]glutamate from rat caudial trigeminal nucleus slices. Pain 93: 191-196
6. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P and Perucca E (2002). Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference (EILAT VI). Epilepsy Res 51: 31-71
7. Taylor CP, Vartanian MG, Yuen PW, Bigge C, Suman-Chauhan N and Hill DR (1993). Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res 14: 11-15
8. Stewart BH, Kugler AR, Thompson PR and Bockbrader HN (1993). A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10: 276-281
9. Beydoun A, Uthman BM and Sackellares JC (1995). Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 18: 469-481
10. French JA, Kugler AR, Robbins JL, Knapp LE and Garofalo EA (2003). Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60: 1631-1637
11. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE and Garofalo EA (2004). Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45: 20-27
12. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M and Stein MB (2004). Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24: 141-149
13. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK and Targum SD (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23: 240-249
14. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT and Weisler R (2003). Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160: 533-540
15. Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E and Maisonobe P (2004). Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109: 26-35
16. Dworkin RH, Corbin AE, Sharma U, LaMoreaux L, Bockbrader H and Young JP (2003). Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60: 1274-1283
17. Hill CM, Balkenohl M, Thomas DW, Walker R, Mathe H and Murray G (2001). Pregabalin in patients with postoperative dental pain. Eur J Pain 5: 119-124
18. Gidal BE, Maly MM, Nemire RE and Haley K (1995). Weight gain and gabapentin therapy. Ann Pharmacother 29: 1048
19. DeToledo JC, Toledo C, DeCerce J and Ramsay RE (1997). Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 19: 394-396
20. Wilton LV and Shakir S (2002). A postmarketing surveillance study of gabapentin as addon therapy for 3,100 patients in England. Epilepsia 43: 983-992
21. Flegal KM, Carroll MD, Kuczmarski RJ and Johnson CL (1998). Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 22: 39-47
22. Must A, Spadano J, Coakley EH, Field AE, Colditz G and Dietz WH (1999). The disease burden associated with overweight and obesity. JAMA 282: 1523-1529
23. National Institutes of Health/National Heart Lung and Blood Institute (1998). Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 6: 51S-209S
24. Troiano RP, Sobal J, Levitsky DA and Frongillo EA (1996). The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J of Obes Relat Metab Disord 20: 63-75
25. McLachlan G and Peel D (2000). Finite mixture models. John Wiley, New York
26. Beal SL, Sheiner LB (eds) (1998). NONMEM users guide VII; conditional estimation methods. Globomax Hanover, Maryland
27. Cockcroft DW and Gault MH (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
28. Beal SL, Sheiner LB (eds) (1989-1998) NONMEM Users guides I-VIII. Globomax, Hanover, Maryland
29. Carrol RJ and Ruppert D (1988). Transformation and weighting in regression. Chapman and Hall, New York
30. Beal SL (2005). Conditioning on certain random events associated with statistical variability in PK/PD. J Pharmacokinet Pharmacodyn 32: 213-243
31. Fattinger KE, Sheiner LB and Verotta D (1995). A new method to explore the distribution of interindividual random effects in nonlinear mixed effects models. Biometrics 51: 1236-1251
32. Gelman A, Carlin JB, Stern HS and Rubin DB (2004). Bayesian data analysis. Chapman and Hall/CRC, Boca Raton
33. Oberg A and Davidian M (2000). Estimating data transformations in nonlinear mixed effects models. Biometrics 56: 65-72
34. Hong CJ, Lin CH, Yu YWY, Yang KH and Tsai SJ (2001). Genetic variants in the serotonin system and weight change during clozapine treatment. Pharmacogenetics 11: 265-268
35. Kinon BJ, Basson BR, Gilmore JA and Tollefson GD (2001). Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62: 92-100
36. Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR and Chang WH (2003). Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 64: 316-320